The irritable bowel syndrome

Medical Clinics of North America

Volumn 86, Issue 6, 2002, Pages 1525-1551

  Hasler, William L ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETROPIUM; CITALOPRAM; DESIPRAMINE; DICYCLOVERINE; DILTIAZEM; LAXATIVE; LOPERAMIDE; MAGNESIUM HYDROXIDE; MEBEVERINE; MIANSERIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OPIATE; OTILONIUM BROMIDE; PAPAVERINE; PINAVERIUM; PRIFINIUM BROMIDE; SCOPOLAMINE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMEBUTINE; TRIMIPRAMINE; UNINDEXED DRUG; ZAMIFENACIN;

CLINICAL TRIAL; COUNSELING; DIET THERAPY; DISEASE SEVERITY; HUMAN; IMMUNE SYSTEM; INTESTINE; IRRITABLE COLON; MOTONEURON; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY; REVIEW;

CENTRAL NERVOUS SYSTEM; COLONIC DISEASES, FUNCTIONAL; DIETARY FIBER; GASTROINTESTINAL MOTILITY; HUMANS; PARASYMPATHOLYTICS;

EID: 0036865959     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(02)00086-X     Document Type: Review

References (119)

1. Thompson WG, Longstreth G, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. In: Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE, editors. Rome II: The Functional Gastrointestinal Disorders. 2nd Edition. McLean, VA: Degnon Associates; 2000. p. 351-432.
2. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987;92:1282-4.
3. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: Prevalence, characteristics, and referral. Gut 2000;46:78-82.
4. Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654-60.
5. Creed F, Ratcliffe J, Fernandez L, et al. Health-related quality of life and health costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001;134:860-8.
6. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders: Prevalence, sociodemography and health impact. Dig Dis Sci 1993;38:1569-80.
7. Walker LS, Guite JW, Duke M, et al. Recurrent abdominal pain: A potential precursor of irritable bowel syndrome in adolescents and young adults. J Pediatr 1998;132:1010-5.
8. Zuckerman MJ, Guerra LG, Drossman DA, et al. Comparison of bowel patterns in Hispanics and non-Hispanic whites. Dig Dis Sci 1995;40:1763-9.
9. Talley NJ, Boyce PM, Jones M. Predictors of health care seeking for irritable bowel syndrome: A population based study. Gut 1997;41:394-8.
10. Hahn B, Watson M, Yan S, et al. Irritable bowel syndrome symptom patterns: Frequency, duration, and severity. Dig Dis Sci 1998;43:2715-8.
11. Lembo T, Naliboff B, Munakata J, et al. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol 1999;94:1320-6.
12. Kennedy TM, Jones RH, Hungin AP, et al. Irritable bowel syndrome, gastro-esophageal reflux, and bronchial hyper-responsiveness in the general population. Gut 1998;43:770-4.
13. Schmulson M, Lee OY, Chang L, et al. Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am J Gastroenterol 1999;94:2929-35.
14. Fass R, Fullerton S, Naliboff B, et al. Sexual dysfunction in patients with irritable bowel syndrome and non-ulcer dyspepsia. Digestion 1998;59:79-85.
15. Sperber AD, Atzmon Y, Neumann L, et al. Fibromyalgia in the irritable bowel syndrome: Studies of prevalence and clinical implications. Am J Gastroenterol 1999;94:3541-6.
16. Locke GR, Zinsmeister AR, Talley NJ, et al. Risk factors for irritable bowel syndrome: Role of analgesics and food sensitivities. Am J Gastroenterol 2000;95:157-65.
17. Sarna SK. Physiology and pathophysiology of colonic motor activity. Dig Dis Sci 1991;36:827-62.
18. Rogers J, Henry MM, Misiewicz JJ. Increased segmental activity and intraluminal pressures in the sigmoid colon of patients with the irritable bowel syndrome. Gut 1989;30:634-41.
19. Chey WY, Jin HO, Lee MH, et al. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001;96:1499-506.
20. Kingham JGC, Bown R, Colson R, Clark ML. Jejunal motility in patients with functional abdominal pain. Gut 1984;25:375-80.
21. Kellow JE, Gill RC, Wingate DL. Prolonged ambulant recordings of small bowel motility demonstrate abnormalities in the irritable bowel syndrome. Gastroenterology 1990;98:1208-18.
22. Simren M, Castedal M, Svedlund J, et al. Abnormal propagation pattern of duodenal pressure waves in the irritable bowel syndrome. Dig Dis Sci 2000;45:2151-61.
23. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987;92:1885-93.
24. Lasser RB, Bond JH, Levitt MD. The role of intestinal gas in functional abdominal pain. N Engl J Med 1975;293:524-6.
25. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001;48:14-9.
26. Serra J, Azpiroz F, Malagelada JR. Mechanisms of intestinal gas retention in humans: Impaired propulsion versus obstructed evacuation. Am J Physiol 2001;281:G138-43.
27. Whitehead WE, Engel BT, Schuster MM. Irritable bowel syndrome: Physiological and psychological differences between diarrhea-predominant and constipation-predominant patients. Dig Dis Sci 1980;25:404-13.
28. Whitehead WE, Palsson OS. Is rectal pain sensitivity a biological marker for irritable bowel syndrome? Psychological influences on pain perception. Gastroenterology 1998;115:1263-71.
29. Simren M, Abrahamsson H, Bjornsson E. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 2001;48:20-7.
30. Chang L, Munakata J, Mayer EA, et al. Perceptual responses in patients with inflammatory and functional bowel disease. Gut 2000;47:497-505.
31. Schmulson M, Chang L, Naliboff B, et al. Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients. Am J Gastroenterol 2000;95:152-6.
32. Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109:40-52.
33. Lembo T, Naliboff BD, Matin K, et al. Irritable bowel syndrome patients show altered sensitivity to exogenous opioids. Pain 2000;87:137-47.
34. Verne GN, Robinson ME, Price DD. Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain 2001;93:7-14.
35. Chan YK, Herkes GK, Badcock C, et al. Alterations in cerebral potentials evoked by rectal distension in irritable bowel syndrome. Am J Gastroenterol 2001;96:2413-7.
36. Silverman DH, Munakata JA, Ennes H, et al. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 1997;112:64-72.
37. Mertz H, Morgan V. Tanner G, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000;118:842-8.
38. Creed F, Guthrie E. Psychological factors in the irritable bowel syndrome. Gut 1987;28:1307-18.
39. Gibbs-Gallagher N, Palsson OS, Levy RL, et al. Selective recall of gastrointestinalsensation words: Evidence for a cognitive-behavioral contribution to irritable bowel syndrome. Am J Gastroenterol 2001;96:1133-8.
40. Levy RL, Cain KC, Jarrett M, Heitkemper MM. The relationship between daily life stress and gastrointestinal symptoms in women with irritable bowel syndrome. J Behav Med 1997;20:177-93.
41. Bennett EJ, Tennant CC, Piesse C, et al. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 1998;43:256-61.
42. Heitkemper M, Charman AB, Shaver J, et al. Self-report and polysomnographic measures of sleep in women with irritable bowel syndrome. Nurs Res 1998;47:270-7.
43. Drossman DA, Leserman J, Nachman G, et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med 1990;113:828-33.
44. Ali A, Toner BB, Stuckless N, et al. Emotional abuse, self-blame, and self-silencing in women with irritable bowel syndrome. Psychosom Med 2000;62:76-82.
45. King TS, Ella M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998;352:1187-9.
46. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503-6.
47. Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhea. Lancet 1996;347:150-3.
48. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804-11.
49. Thornley JP, Jenkins D, Neal K, et al. Relationship of Campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome. J Infect Dis 2001;184:606-9.
50. Fernandez-Banares F, Esteve-Pardo M, de Leon R, et al. Sugar malabsorption in functional bowel disease: Clinical implications. Am J Gastroenterol 1993;88:2044-50.
51. Dainese R, Galliani EA, De Lazzari F, et al. Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients. Am J Gastroenterol 1999;94:1892-7.
52. Niec AM, Frankum B, Talley NJ. Are adverse food reactions linked to irritable bowel syndrome? Am J Gastroenterol 1998;93:2184-90.
53. Aggarwal A, Cutts TF, Abell TL, et al. Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities. Gastroenterology 1994;106:945-50.
54. Elsenbruch S, Orr WC. Diarrhea- and constipation-predominant IBS patients differ in postprandial autonomic and cortisol responses. Am J Gastroenterol 2001;96:460-6.
55. Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: A pilot study. Gut 1998;42:42-6.
56. Bose M, Nickols C, Feakins R, Farthing M. 5-Hydroxytryptamine and enteroendocrine cells in the irritable bowel syndrome [abstract]. Gastroenterology 2000;118:2949.
57. Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: A prevalence study. Am J Gastroenterol 1998;93:1867-72.
58. Houghton LA, Jackson NA, Whorwell PJ, Morris J. Do male sex hormones protect from irritable bowel syndrome? Am J Gastroenterol 2000;95:2296-300.
59. Locke GR, Zinsmeister AR, Talley NJ, et al. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 2000;75:907-12.
60. Morris-Yates A, Talley NJ, Boyce PM, et al. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol 1998;93:1311-7.
61. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. BMJ 1978;2:653-4.
62. Kruis W, Thieme C, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome: Its value in the exclusion of organic disease. Gastroenterology 1984;87:1-7.
63. Talley NJ, Phillips SF, Melton LJ, et al. Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut 1990;31:77-81.
64. Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999;94:2912-7.
65. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: A technical review for practice guideline development. Gastroenterology 1997;112:2120-36.
66. Tolliver BA, Herrera JL, DiPalma JA. Evaluation of patients who meet clinical criteria for irritable bowel syndrome. Am J Gastroenterol 1994;89:176-8.
67. Hamm LR, Sorrells SC, Harding JP, et al. Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria. Am J Gastroenterol 1999;94:1279-82.
68. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: Long-term prognosis and the physician-patient interaction. Ann Intern Med 1995;122:107-12.
69. Klein KB. Controlled clinical trials in the irritable bowel syndrome: A critique. Gastroenterology 1988;95:232-41.
70. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: A review of randomised controlled trials. Gut 2001;48:272-82.
71. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of irritable bowel syndrome: A systematic review of randomized, controlled trials. Ann Intern Med 2000;133:136-47.
72. Payler DK, Pomare EW, Heaton KW, Harvey RF. The effect of wheat bran on intestinal transit. Gut 1975;16:209-13.
73. Muller-Lissner SA. Effect of wheat bran on weight of stool and gastrointestinal transit time: A meta analysis. BMJ 1988;296:615-7.
74. Hotz J, Plein K. Effectiveness of plantago seed husks in comparison with wheat bran on stool frequency and manifestations of irritable colon syndrome with constipation. Med Klin 1994;89:645-51.
75. Woolner JT, Kirby GA. Clinical audit of the effects of low-fibre diet on irritable bowel syndrome. J Human Nutr Diet 2000;13:249-53.
76. Cleveland MV, Flavin DP, Ruben RA, et al. New polyethylene glycol laxative for treatment of constipation in adults: A randomized, double-blind, placebo-controlled study. South Med J 2001;94:478-81.
77. Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984;29:239-47.
78. Smith MI, Cherian P, Raju GS, et al. Bile acid malabsorption in persistent diarrhea. J R Coll Physicians Lond 2000:34:448-51.
79. Dave B, Rubin W. Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea. Dig Dis Sci 1999;44:1893-8.
80. Snape WJ, Wright SH, Battle WM, Cohen S. The gastrocolic response: Evidence for a neural mechanism. Gastroenterology 1979;77:1235-40.
81. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:499-510.
82. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15:355-61.
83. 3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1997;11:561-8.
84. Battaglia G, Morselli-Labate AM, Camarri E, et al. Otilonium bromide in irritable bowel syndrome: A double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther 1998;12:1003-10.
85. Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: A critical review and metaanalysis. Am J Gastroenterol 1998;93:1131-5.
86. Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 1998;13:738-41.
87. Greenbaum DS, Mayle JE, Vanegeren LE, et al. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 1987;32:257-66.
88. Tack JF, Vos R, Broekaert D, et al. Influence of citalopram, a selective serotonin reuptake inhibitor, on colonic tone and sensitivity in man [abstract]. Gastroenterology 2000;118:998.
89. Broekaert D, Vos R, Gevers AM, et al. A double-blind randomised placebo-controlled crossover trial of citalopram, a selective 5-hydroxytryptamine reuptake inhibitor, in irritable bowel syndrome [abstract]. Gastroenterology 2001;120:3250.
90. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: A meta-analysis. Am J Med 2000;108:65-72.
91. Clouse RE, Prakash C, Anderson RJ, Lustman PJ. Antidepressants for functional gastrointestinal symptoms and syndromes: A meta-analysis [abstract]. Gastroenterology 2001;120:3252.
92. Delvaux M, Louvel D, Mamet JP, et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998;12:849-55.
93. Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: A role in irritable bowel syndrome and functional dyspepsia? Aliment Pharmacol Ther 1996;10:595-9.
94. 3 receptor antagonist. Aliment Pharmacol Ther 1999;13:1149-59.
95. Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, placebocontrolled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000;14:23-34.
96. Wolfe SG, Chey WY, Washington MK, et al. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am J Gastroenterol 2001;96:803-11.
97. Friedel D, Thomas R, Fisher RS. Ischemic colitis during treatment with alosetron. Gastroenterology 2001;20:557-60.
98. Caras S, Krause G, Biesheuvel E, Steinborn C. Cilansetron shows efficacy in male and female non-constipated patients with irritable bowel syndrome in a United States study [abstract]. Gastroenterology 2001;120:1139.
99. 4 receptor antagonism in irritable bowel syndrome: Effect of SB-207266-A on rectal sensitivity and small bowel transit. Aliment Pharmacol Ther 1999;13:1437-44.
100. Van Outryve M, Milo R, Toussaint J, Van Eeghem P. "Prokinetic" treatment of constipation-predominant irritable bowel syndrome: A placebo-controlled study of cisapride. J Clin Gastroenterol 1991;13:49-57.
101. Prather C, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-8.
102. Camilleri M. Review article: Tegaserod. Aliment Pharmacol Ther 2001;15:277-89.
103. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120:354-60.
104. Mathias JR, Clench MH, Abell TL, et al. Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: A double-blind, placebo-controlled, randomized study. Dig Dis Sci 1998;43:1347-55.
105. Suarez F, Levitt MD, Adshead J, Barkin JS. Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. Dig Dis Sci 1999;44:1317-21.
106. DiStefano M, Strocchi A, Malservisi S, et al. Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther 2000;14:1001-8.
107. Grazioli I, Malzi G, Balsamo V, et al. Food intolerance and irritable bowel syndrome of childhood: Clinical efficacy of oral sodium cromoglycate and elimination diet. Minerva Pediatr 1993;45:253-8.
108. 1A agonist buspirone on rectal tone and on the perception of rectal distention in man [abstract]. Gastroenterology 1998;114:G3046.
109. Malcolm A, Camilleri M, Kost L, et al. Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function. Aliment Pharmacol Ther 2000;14:783-93.
110. Lee OY, Munakata J, Naliboff BD, et al. A double-blind parallel group pilot study of the effects of CJ-11,974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients [abstract]. Gastroenterology 2000;118:4439.
111. Hasler WL, Soudah HC, Owyang C. Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients. J Pharmacol Exp Ther 1994;268:1206-11.
112. Talley NJ, Owen BK, Boyce P, Paterson K. Psychological treatments for irritable bowel syndrome: A critique of controlled treatment trials. Am J Gastroenterol 1996;91:277-83.
113. Heymann-Monnikes I, Arnold R, Florin I, et al. The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Am J Gastroenterol 2000;95:981-94.
114. Houghton LA, Heyman DJ, Whorwell PJ. Symptomatology, quality of life and economic features of irritable bowel syndrome: The effect of hypnotherapy. Aliment Pharmacol Ther 1996;10:91-5.
115. Kames LD, Rapkin AJ, Naliboff BD, et al. Effectiveness of an interdisciplinary pain management program for the treatment of chronic pelvic pain. Pain 1990;41:41-6.
116. Nobaek S, Johansson ML, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-8.
117. Bensoussan A, Talley NJ, Hing M, et al. Treatment of irritable bowel syndrome with Chinese herbal medicine: A randomized controlled trial. JAMA 1998;280:1585-9.
118. Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: A 5-year prospective study. Lancet 1987;1:963-5.
119. van Dulmen AM, Fennis JF, Mokkink HG, et al. Persisting improvement in complaintrelated cognitions initiated during medical consultations in functional abdominal complaints. Psychol Med 1997;27:725-9.